Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.

We report the identification of three structurally diverse compounds - compound 4, GC376, and MAC-5576 - as inhibitors of the SARS-CoV-2 3CL protease. Structures of each of these compounds in complex with the protease revealed strategies for further development, as well as general principles for designing SARS-CoV-2 3CL protease inhibitors. ...
These compounds may therefore serve as leads for the basis of building effective SARS-CoV-2 3CL protease inhibitors.
Mesh Terms:
COVID-19 Drug Treatment, Coronavirus 3C Proteases, Crystallography, X-Ray, Drug Evaluation, Preclinical, Humans, Pyrrolidines, SARS-CoV-2, Sulfonic Acids, Virus Replication
Nat Commun
Date: Apr. 01, 2021
Download Curated Data For This Publication
245635
Switch View:
  • Interactions 2